
Quarterly report 2024-Q3
added 11-14-2024
Acutus Medical Net Debt 2011-2026 | AFIB
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Acutus Medical
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 14.2 M | 9.17 M | 16.7 M | 25.1 M | 31.7 M | 16.2 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 31.7 M | 9.17 M | 18.8 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Medical devices industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Aziyo Biologics
AZYO
|
1.36 M | - | 1.37 % | $ 20.5 M | ||
|
GenMark Diagnostics, Inc.
GNMK
|
38.7 M | - | - | $ 1.77 B | ||
|
Conformis
CFMS
|
-26.2 M | - | - | $ 16.4 M | ||
|
Bruker Corporation
BRKR
|
1.91 B | $ 39.03 | -0.61 % | $ 5.82 K | ||
|
Cardiovascular Systems
CSII
|
-64.6 M | - | 0.15 % | $ 844 M | ||
|
Cutera
CUTR
|
-140 M | - | -10.19 % | $ 1.99 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
6.46 M | - | -5.86 % | $ 30.6 M | ||
|
Dynatronics Corporation
DYNT
|
1.8 M | - | 14.99 % | $ 929 K | ||
|
Eargo
EAR
|
-97.8 M | - | - | $ 10.2 M | ||
|
Cognyte Software Ltd.
CGNT
|
-47.4 M | $ 8.1 | 3.58 % | $ 582 M | ||
|
Allied Healthcare Products
AHPI
|
-3.31 M | - | 3.58 % | $ 2.21 M | ||
|
Second Sight Medical Products
EYES
|
961 K | - | -0.97 % | $ 54.4 M | ||
|
AdaptHealth Corp.
AHCO
|
1.64 B | $ 9.61 | 2.23 % | $ 1.3 B | ||
|
Apollo Endosurgery
APEN
|
-22.5 M | - | - | $ 475 M | ||
|
EDAP TMS S.A.
EDAP
|
-22.8 M | $ 4.1 | 2.76 % | $ 153 M | ||
|
Electromed
ELMD
|
-10.5 M | $ 24.46 | 2.02 % | $ 207 M | ||
|
CONMED Corporation
CNMD
|
802 M | $ 43.13 | -0.43 % | $ 1.34 B | ||
|
CryoLife, Inc.
CRY
|
230 M | - | -4.14 % | $ 702 M | ||
|
FONAR Corporation
FONR
|
-42.8 M | $ 18.54 | 0.22 % | $ 122 M | ||
|
Avinger
AVGR
|
-16.3 M | - | -20.74 % | $ 369 K | ||
|
AxoGen
AXGN
|
15.2 M | $ 29.55 | -0.94 % | $ 1.36 B | ||
|
Apyx Medical Corporation
APYX
|
-10.1 M | $ 3.29 | 3.78 % | $ 114 M | ||
|
Axonics Modulation Technologies
AXNX
|
-230 M | - | - | $ 3.31 B | ||
|
Soliton, Inc.
SOLY
|
-31.6 M | - | -1.42 % | $ 435 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
-9.02 K | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
-2.3 M | - | 0.03 % | $ 1.58 B | ||
|
Accuray Incorporated
ARAY
|
73.7 M | $ 0.52 | -0.99 % | $ 53.4 M | ||
|
Misonix, Inc.
MSON
|
5.72 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
-4.95 M | - | - | $ 111 M | ||
|
Medigus Ltd.
MDGS
|
-6.43 M | - | 10.28 % | $ 55.5 M | ||
|
Cytosorbents Corporation
CTSO
|
11.2 M | $ 0.79 | -1.19 % | $ 43 M | ||
|
Align Technology
ALGN
|
-925 M | $ 182.25 | -0.21 % | $ 13.6 B | ||
|
Intersect ENT, Inc.
XENT
|
50.8 M | - | - | $ 955 M | ||
|
Inari Medical
NARI
|
-27.9 M | - | - | $ 4.23 B | ||
|
Butterfly Network
BFLY
|
-65.9 M | $ 4.01 | 8.38 % | $ 849 M | ||
|
BIOLASE
BIOL
|
6.1 M | - | -13.19 % | $ 166 K | ||
|
Abbott Laboratories
ABT
|
1.65 B | $ 113.33 | -0.22 % | $ 197 B | ||
|
NuVasive
NUVA
|
-238 M | - | - | $ 2.07 B | ||
|
Nevro Corp.
NVRO
|
93.4 M | - | - | $ 217 M | ||
|
BioSig Technologies
BSGM
|
252 K | - | 37.08 % | $ 85.7 M | ||
|
Boston Scientific Corporation
BSX
|
9.26 B | $ 72.95 | -1.22 % | $ 108 B | ||
|
InMode Ltd.
INMD
|
-34.8 M | $ 13.55 | -0.37 % | $ 876 M | ||
|
IRIDEX Corporation
IRIX
|
-4.29 M | $ 1.43 | - | $ 23.1 M | ||
|
IRadimed Corporation
IRMD
|
-52.1 M | $ 105.71 | 1.36 % | $ 1.34 B | ||
|
Helius Medical Technologies
HSDT
|
-5.12 M | $ 2.27 | 14.65 % | $ 1.38 M | ||
|
Alphatec Holdings
ATEC
|
347 M | $ 13.13 | 0.84 % | $ 1.97 B | ||
|
Edwards Lifesciences Corporation
EW
|
-2.32 B | $ 85.6 | 0.39 % | $ 50.1 B |